Publications, Pharmaceutical

Demonstrating bioequivalence for generic fluticasone propionate OINDPs

Optimal strategies for demonstrating bioequivalence for commonly used inhaled drugs are highly relevant to the cost-effective development of generics.

This paper considers the use of pharmacokinetics in the demonstration of the bioequivalence of fluticasone propionate inhalation products, without the need for comparative clinical endpoint studies. Compartmental and non-compartmental pharmacokinetic analyses for three alternative fluticasone dry powder inhaler formulations are examined. These data showed good agreement with formulation characteristics measured using in vitro methods and highlight the potential to use pharmacokinetic studies to assess the dose accessible to the lungs, regional deposition, and pulmonary residence time. The work illustrates how batch-to-batch differences in adjuvant or excipient properties influence pharmacokinetics, providing helpful guidance for those developing generic products.

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

3 Jul 2023

Orally Inhaled Drug products; Bioequivalence Models

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
24 Apr 2023

Navigating pMDI Reformulation 2.0

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Device Innovations

Read More
19 Apr 2023

Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges

Publications, Pharmaceutical, Product Solutions, Sustainability, Brand Differentiation, Market Insights

Read More
1 2 3 4 5 19
Back To Top